Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.

Sarkaria JN, Ballman KV, Kizilbash SH, Sulman EP, Giannini C, Friday BB, Butowski NA, Mohile NA, Piccioni DE, Battiste JD, Drappatz J, Campian JL, Mashru S, Jaeckle KA, O'Brien BJ, Dixon JG, Kabat BF, Laack NL, Hu LS, Kaufmann T, Kumthekar P, Ellingson BM, Anderson SK, Galanis E.

Open source

DOI: 10.1001/jamaoncol.2024.4361
Published: 2024-12-01
Container: JAMA Oncol
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamaoncol.2024.4361,
  title = {Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.},
  author = {Sarkaria JN and  Ballman KV and  Kizilbash SH and  Sulman EP and  Giannini C and  Friday BB and  Butowski NA and  Mohile NA and  Piccioni DE and  Battiste JD and  Drappatz J and  Campian JL and  Mashru S and  Jaeckle KA and  O'Brien BJ and  Dixon JG and  Kabat BF and  Laack NL and  Hu LS and  Kaufmann T and  Kumthekar P and  Ellingson BM and  Anderson SK and  Galanis E.},
  year = {2024},
  journal = {JAMA Oncol},
  doi = {10.1001/jamaoncol.2024.4361},
  url = {https://doi.org/10.1001/jamaoncol.2024.4361}
}

RIS

TY  - JOUR
TI  - Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.
AU  - Sarkaria JN
AU  -  Ballman KV
AU  -  Kizilbash SH
AU  -  Sulman EP
AU  -  Giannini C
AU  -  Friday BB
AU  -  Butowski NA
AU  -  Mohile NA
AU  -  Piccioni DE
AU  -  Battiste JD
AU  -  Drappatz J
AU  -  Campian JL
AU  -  Mashru S
AU  -  Jaeckle KA
AU  -  O'Brien BJ
AU  -  Dixon JG
AU  -  Kabat BF
AU  -  Laack NL
AU  -  Hu LS
AU  -  Kaufmann T
AU  -  Kumthekar P
AU  -  Ellingson BM
AU  -  Anderson SK
AU  -  Galanis E.
PY  - 2024
JO  - JAMA Oncol
DO  - 10.1001/jamaoncol.2024.4361
UR  - https://doi.org/10.1001/jamaoncol.2024.4361
ER  -

APA

JN, S., KV, B., SH, K., EP, S., C, G., BB, F., NA, B., NA, M., DE, P., JD, B., J, D., JL, C., S, M., KA, J., BJ, O., JG, D., BF, K., NL, L., LS, H., T, K., P, K., BM, E., SK, A., & E., G. (2024). Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2024.4361

Source records

europe-pmc · retrieved 2026-09-27T05:55:02.535Z